When combined, the new inhibitor and existing therapy enhance each other’s anti-cancer effects MUSC
A research team at the Medical University of South Carolina (MUSC) has developed new compounds that show early promise in the fight against the rare pediatric cancer neuroblastoma when paired with the existing cancer drug bortezomib (Velcade, Takeda Oncology). The new compounds block or inhibit an enzyme known as lysine-specific demethylase 1 (LSD1). The MUSC …